This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Leerink Partners Keeps Their Hold Rating on CureVac (CVAC)

Tipranks - Tipranks - Wed Aug 20, 2025

In a report released on August 15, Mani Foroohar from Leerink Partners maintained a Hold rating on CureVac. The company’s shares opened today at $5.46.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

According to TipRanks, Foroohar is an analyst with an average return of -5.9% and a 44.38% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as RegenXBio, Moderna, and Arrowhead Pharmaceuticals.

Currently, the analyst consensus on CureVac is a Hold with an average price target of $4.63.

See today’s best-performing stocks on TipRanks >>

Based on CureVac’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $893 thousand and a GAAP net loss of $52.08 million. In comparison, last year the company earned a revenue of $12.37 million and had a GAAP net loss of $70.55 million

Read More on CVAC:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).